背景：肝细胞癌（HCC）患者的死亡率和预后众所周知。多种高度恶性的人类癌症表达有丝分裂阻滞缺陷2样1（MAD2L1），在它们的发育和发展中起关键作用的转录因子。然而,MAD2L1对肝癌的具体机制和影响仍不确定。
方法：我们在本研究中使用癌症基因组图谱和基因型-组织表达数据对MAD2L1预后和表达进行了全癌分析。MAD2L1可能作为肝癌的癌基因，以及计算机模拟分析的组合，包括表达式，生存,和相关分析，进行鉴定有助于MAD2L1过表达的非编码核糖核酸(ncRNAs)。
结果：总之，基于其上游ncRNA相关通路，MAD2L1在HCC中很可能受到HCP5/miRNA-139-5p/MAD2L1的调控。MAD2L1水平与肿瘤免疫细胞浸润之间也存在显著正相关，免疫细胞生物标志物，和免疫检查点表达。
结论：我们的研究结果表明，ncRNA介导的MAD2L1在HCC中的上调与不良预后和肿瘤浸润密切相关。
BACKGROUND: The mortality rate and prognosis of patients with hepatocellular carcinoma (HCC) are well known. A variety of highly malignant human cancers express mitotic arrest deficient 2 like 1 (MAD2L1), a transcription factor that plays a critical role in their development and progression. However, MAD2L1\'s particular mechanisms and effects on HCC remain uncertain.
METHODS: We performed a pan-cancer analysis for MAD2L1 prognosis and expression using The Cancer Genome Atlas and Genotype-Tissue Expression data in the present study. MAD2L1 may act as an oncogene in HCC, and a combination of in silico analyses, including expression, survival, and correlation analyses, were performed to identify non-coding ribonucleic acids (ncRNAs) that contribute to MAD2L1 overexpression.
RESULTS: In conclusion, MAD2L1 is most likely regulated by HCP5/miRNA-139-5p/MAD2L1 in HCC based on its upstream ncRNA-related pathway. A significant positive association was also found between MAD2L1 levels and tumor immune cell infiltration, immune cell biomarkers, and immune checkpoint expression.
CONCLUSIONS: Our findings demonstrate that ncRNA-mediated upregulation of MAD2L1 in HCC is closely related to poor prognosis and tumor infiltration.
